- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-19
DOI
10.1007/s11523-020-00758-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selinexor‐based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
- (2020) Ajai Chari et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
- (2020) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
- (2020) Cristina Gasparetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
- (2020) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells
- (2019) GORDON T. BOLGER et al. ANTICANCER RESEARCH
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and safety of selinexor in recurrent glioblastoma.
- (2019) Andrew B. Lassman et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- 466PInterim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours
- (2019) J Wang et al. ANNALS OF ONCOLOGY
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Darrell White et al. Clinical Lymphoma Myeloma & Leukemia
- New generation drugs for treatment of multiple myeloma
- (2019) Fehaid Alanazi et al. DRUG DISCOVERY TODAY
- XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach
- (2019) Venkatesh Chanukuppa et al. Journal of Proteomics
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
- (2018) Christian Argueta et al. Oncotarget
- A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
- (2018) Richard Greil et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
- (2017) Vincent Camus et al. Journal of Hematology & Oncology
- Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
- (2017) Barbara Muz et al. Translational Oncology
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
- (2016) Z A Hing et al. LEUKEMIA
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
- (2015) S. Rosebeck et al. MOLECULAR CANCER THERAPEUTICS
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
- (2015) Zheng-Lan Huang et al. Oncotarget
- Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups
- (2014) Patricia Gomez-Bougie et al. CANCER BIOLOGY & THERAPY
- Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma
- (2014) K. Martin Kortuem et al. Clinical Lymphoma Myeloma & Leukemia
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas
- (2013) Fang Zhou et al. MEDICAL ONCOLOGY
- CRM1 Is a Cellular Target of Curcumin: New Insights for the Myriad of Biological Effects of an Ancient Spice
- (2013) Mingshan Niu et al. TRAFFIC
- CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
- (2013) Joel G. Turner et al. Journal of Cancer
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study
- (2012) Terry Golombick et al. AMERICAN JOURNAL OF HEMATOLOGY
- Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors
- (2012) Ori Kalid et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation
- (2012) Biljana Culjkovic-Kraljacic et al. Cell Reports
- Nuclear export of proteins and drug resistance in cancer
- (2011) Joel G. Turner et al. BIOCHEMICAL PHARMACOLOGY
- CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
- (2011) K. Sakakibara et al. BLOOD
- Aprepitant: drug-drug interactions in perspective
- (2010) M. S. Aapro et al. ANNALS OF ONCOLOGY
- Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
- (2009) J. G. Turner et al. CANCER RESEARCH
- Curcumin: From ancient medicine to current clinical trials
- (2008) H. Hatcher et al. CELLULAR AND MOLECULAR LIFE SCIENCES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started